


IFW



RIP:cms 08/25/05 6565-68316-01 422196 93231-53

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Yi-Yan Yang, et al.

**Application No.** 10/815,987

**Filed:** March 31, 2004

**Confirmation No.** 7283

**For:** SUSTAINED-RELEASE TABLET  
FORMULATION

**Examiner:** Thurman K. Page

**Art Unit:** 1615

**Attorney Reference No.** 6565-68316-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent  
for Applicant(s)

Date Mailed August 25, 2005

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language and/or non-English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.


Applicants are filing this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

  
Richard J. Polley  
Registration No. 28,107

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

cc: Client  
Docketing



(2-92)  
Sheet 1 of 1

<b>FORM PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>	<b>Docket Number (Optional)</b>  6565-68316-01/RJP	<b>Application Number</b>  10/815,987
	<b>Applicant</b> YANG, YI YAN ET AL.	
	<b>Filing Date</b> March 31, 2004	<b>Group Art Unit</b> 1614

U.S. PATENT DOCUMENTS						
EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
	WO 2002/067905A		PCT				
	03-193734		JP				

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
		Durig T. et al. "Mechanistic Evaluation of Binary Effects of Magnesium Stearate and Talc as Dissolution Retardants at 85% Drug Loading in an Experimental Extended-Release Formulation". <i>J. Pharm Sci</i> 1997, Oct; 86(10):1092-8. See page 1093
		Saha R.N. et al. "A Comparative Study of Controlled Release Matrix Tablets of Diclofenac Sodium, Ciprofloxacin Hydrochloride, and Theophylline". <i>Drug Deliv.</i> 2001, Jul-Aug; 8(3): 149-54. See page 149, Table 1 and Fig. 3.
		Leslie S., "The Contin delivery system: dosing considerations". <i>J. Allergy Clin Immunol.</i> 1986, Oct. (78) (4 Pt 2): 768-73. See page 768 and Fig. 2
		Prabakaran D. et al. "Modified push-pull osmotic system for simultaneous delivery of theophylline and salbutamol: development and in vitro characterization". <i>Int J. Pharm.</i> 2004 October 13; 284(1-2): 95-108. See Abstract, Table 1-4
<b>EXAMINER:</b>		<b>DATE CONSIDERED:</b>
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.		